Evidence map›Paper›PMID 34350176›Full record

ArticleFrontiers in cell and developmental biology2021

Apatinib Suppresses Gastric Cancer Stem Cells Properties by Inhibiting the Sonic Hedgehog Pathway.

Wanshuang Cao, Yuan Li, Hongliang Sun, Chenying Yang, Jianyun Zhu, Chunfeng Xie, Xiaoting Li, Jieshu Wu, Shanshan Geng, Lu Wang and 4 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in cell and developmental biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 5 institutions in 1 country.

Wanshuang CaoCancer Research Division, Center for Global Health, School of Public Health, Nanjing Medical University, Nanjing, China.
Yuan LiDepartment of Clinical Nutrition, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, China.
Hongliang SunDepartment of Urology, Taikang Xianlin Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, China.
Chenying YangCancer Research Division, Center for Global Health, School of Public Health, Nanjing Medical University, Nanjing, China.
Jianyun ZhuSuzhou Digestive Diseases and Nutrition Research Center, Suzhou Municipal Hospital, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou, China.
Chunfeng XieCancer Research Division, Center for Global Health, School of Public Health, Nanjing Medical University, Nanjing, China.
Xiaoting LiCancer Research Division, Center for Global Health, School of Public Health, Nanjing Medical University, Nanjing, China.
Jieshu WuCancer Research Division, Center for Global Health, School of Public Health, Nanjing Medical University, Nanjing, China.
Shanshan GengCancer Research Division, Center for Global Health, School of Public Health, Nanjing Medical University, Nanjing, China.
Lu WangJiangsu Hengrui Medicine Co., Ltd., Lianyungang, China.
Liangfei SunJiangsu Hengrui Medicine Co., Ltd., Lianyungang, China.
Guozhu GengJiangsu Hengrui Medicine Co., Ltd., Lianyungang, China.
Hongyu HanState Key Laboratory of Oncology in South China, Department of Clinical Nutrition, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China.
Caiyun ZhongCancer Research Division, Center for Global Health, School of Public Health, Nanjing Medical University, Nanjing, China.
Nanjing Medical University · CNJiangsu Hengrui Medicine (China) · CNNanjing Drum Tower Hospital · CNSun Yat-sen University Cancer Center · CNSuzhou Municipal Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The presence of gastric cancer stem cells (GCSCs) marks the onset of gastric carcinoma. The sonic hedgehog (SHH) pathway plays a vital role in the maintenance of GCSC characteristics. Apatinib has been approved in China for advanced gastric cancer (GC) treatment. However, whether apatinib can target GCSCs and affect the SHH pathway remains unclear. The present study aimed to investigate the underlying mechanism of apatinib's antitumor effects on GC. The expression levels of GCSC markers and number of CD133

Indexed as

apatinibchemoresistancegastric cancer stem cellssonic hedgehog pathwaysuppression

Identifiers

PMID34350176
PMCPMC8326764
OpenAlexW3109707008

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.